Skip to main content
. Author manuscript; available in PMC: 2023 Jul 18.
Published in final edited form as: Cancer Res. 2023 Jan 18;83(2):301–315. doi: 10.1158/0008-5472.CAN-22-1433

Figure 1. DLL3 Expression by Histologic Subtype of mCRPC.

Figure 1.

a. DLL3 expression by H-score across samples with de novo and t-SCNC (n = 12) versus adenocarcinoma (n = 12) histologic differentiation. b. H&E and IHC stains for DLL3 in de novo and t-SCNC biopsies. Scale bar, 50 μM. c. Overall survival from date of biopsy for patients harboring mCRPC biopsies that were positive vs. negative for DLL3 expression. (HR = hazard ratio; CI = confidence interval). The number at risk for each group is indicated and censored data are indicated by the gray tick marks.